FDA “Follow-On” Biologics Guidance: A Preview
Executive Summary
[CDER Acting Director Galson discussed FDA's upcoming guidance on "follow on" biologics during the Schwab Washington Research Group health care conference May 5. Here is a transcript of his remarks, by "The Pink Sheet".]
You may also be interested in...
FDA Follow-On Biologics Public Meeting Slated For Early ’05
FDA and the Drug Information Association are looking at dates in early 2005 for a public meeting on scientific issues surrounding the development of follow-on biologics
FDA Follow-On Biologics Public Meeting Slated For Early ’05
FDA and the Drug Information Association are looking at dates in early 2005 for a public meeting on scientific issues surrounding the development of follow-on biologics
“Follow-On” Biologics Guidance Will Limit Use Of Data To “Public Domain”
FDA's upcoming draft guidance on follow-on biologics will allow use of data that are in the public domain only, Center for Drug Evaluation & Research acting Director Steven Galson, MD, told the Schwab Soundview Washington Research Group health care conference May 5